American Society for Gastrointestinal Endoscopy-European Society of Gastrointestinal Endoscopy guideline on primary endoscopic bariatric and metabolic therapies for adults with obesity

Pichamol Jirapinyo; Alia Hadefi; Christopher C Thompson; Árpád V Patai; Rahul Pannala; Stefan K Goelder; Vladimir Kushnir; Marc Barthet; Caroline M Apovian; Ivo Boskoski; Christopher G Chapman; Paul Davidson; Gianfranco Donatelli; Vivek Kumbhari; Bu Hayee; Janelle Esker; Tomas Hucl; Aurora D Pryor; Roberta Maselli; Allison R Schulman; Francois Pattou; Shira Zelber-Sagi; Paul A Bain; Valérie Durieux; Konstantinos Triantafyllou; Nirav Thosani; Vincent Huberty; Shelby Sullivan

doi:10.1055/a-2292-2494

American Society for Gastrointestinal Endoscopy-European Society of Gastrointestinal Endoscopy guideline on primary endoscopic bariatric and metabolic therapies for adults with obesity

Pichamol Jirapinyo
, Alia Hadefi^*
, Christopher C Thompson
, Árpád V Patai
, Rahul Pannala
, Stefan K Goelder
, Vladimir Kushnir
, Marc Barthet
, Caroline M Apovian
, Ivo Boskoski
, Christopher G Chapman
, Paul Davidson
, Gianfranco Donatelli
, Vivek Kumbhari
, Bu Hayee
, Janelle Esker
, Tomas Hucl
, Aurora D Pryor
, Roberta Maselli
, Allison R Schulman

Francois Pattou, Shira Zelber-Sagi, Paul A Bain, Valérie Durieux, Konstantinos Triantafyllou, Nirav Thosani, Vincent Huberty, Shelby Sullivan

^*Autore corrispondente per questo lavoro

Risultato della ricerca: Contributo in rivista › Articolo

Abstract

This joint ASGE-ESGE guideline provides an evidence-based summary and recommendations regarding the role of endoscopic bariatric and metabolic therapies (EBMTs) in the management of obesity. The document was developed using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) framework. It evaluates the efficacy and safety of EBMT devices and procedures that currently have CE mark or FDA-clearance/approval, or that had been approved within five years of document development. The guideline suggests the use of EBMTs plus lifestyle modification in patients with a BMI of ?30 kg/m 2, or with a BMI of 27.0-29.9 kg/m 2 with at least 1 obesity-related comorbidity. Furthermore, it suggests the utilization of intragastric balloons and devices for endoscopic gastric remodeling (EGR) in conjunction with lifestyle modification for this patient population.

Lingua originale	Inglese
pagine (da-a)	437-456
Numero di pagine	20
Rivista	Endoscopy
Volume	56
Numero di pubblicazione	6
DOI	https://doi.org/10.1055/a-2292-2494
Stato di pubblicazione	Pubblicato - 2024

All Science Journal Classification (ASJC) codes

Gastroenterologia

Keywords

Endoscopy
Gastrointestinal

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1055/a-2292-2494

Altri file e collegamenti

Cita questo

Jirapinyo, P., Hadefi, A., Thompson, C. C., Patai, Á. V., Pannala, R., Goelder, S. K., Kushnir, V., Barthet, M., Apovian, C. M., Boskoski, I., Chapman, C. G., Davidson, P., Donatelli, G., Kumbhari, V., Hayee, B., Esker, J., Hucl, T., Pryor, A. D., Maselli, R., ... Sullivan, S. (2024). American Society for Gastrointestinal Endoscopy-European Society of Gastrointestinal Endoscopy guideline on primary endoscopic bariatric and metabolic therapies for adults with obesity. Endoscopy, 56(6), 437-456. https://doi.org/10.1055/a-2292-2494

@article{0d60a981cb6f4c91964998ddaf8ca06d,

title = "American Society for Gastrointestinal Endoscopy-European Society of Gastrointestinal Endoscopy guideline on primary endoscopic bariatric and metabolic therapies for adults with obesity",

abstract = "This joint ASGE-ESGE guideline provides an evidence-based summary and recommendations regarding the role of endoscopic bariatric and metabolic therapies (EBMTs) in the management of obesity. The document was developed using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) framework. It evaluates the efficacy and safety of EBMT devices and procedures that currently have CE mark or FDA-clearance/approval, or that had been approved within five years of document development. The guideline suggests the use of EBMTs plus lifestyle modification in patients with a BMI of ?30 kg/m 2, or with a BMI of 27.0-29.9 kg/m 2 with at least 1 obesity-related comorbidity. Furthermore, it suggests the utilization of intragastric balloons and devices for endoscopic gastric remodeling (EGR) in conjunction with lifestyle modification for this patient population.",

keywords = "Endoscopy, Gastrointestinal, Endoscopy, Gastrointestinal",

author = "Pichamol Jirapinyo and Alia Hadefi and Thompson, \{Christopher C\} and Patai, \{{\'A}rp{\'a}d V\} and Rahul Pannala and Goelder, \{Stefan K\} and Vladimir Kushnir and Marc Barthet and Apovian, \{Caroline M\} and Ivo Boskoski and Chapman, \{Christopher G\} and Paul Davidson and Gianfranco Donatelli and Vivek Kumbhari and Bu Hayee and Janelle Esker and Tomas Hucl and Pryor, \{Aurora D\} and Roberta Maselli and Schulman, \{Allison R\} and Francois Pattou and Shira Zelber-Sagi and Bain, \{Paul A\} and Val{\'e}rie Durieux and Konstantinos Triantafyllou and Nirav Thosani and Vincent Huberty and Shelby Sullivan",

year = "2024",

doi = "10.1055/a-2292-2494",

language = "English",

volume = "56",

pages = "437--456",

journal = "Endoscopy",

issn = "1438-8812",

publisher = "Georg Thieme Verlag",

number = "6",

}

Jirapinyo, P, Hadefi, A, Thompson, CC, Patai, ÁV, Pannala, R, Goelder, SK, Kushnir, V, Barthet, M, Apovian, CM, Boskoski, I, Chapman, CG, Davidson, P, Donatelli, G, Kumbhari, V, Hayee, B, Esker, J, Hucl, T, Pryor, AD, Maselli, R, Schulman, AR, Pattou, F, Zelber-Sagi, S, Bain, PA, Durieux, V, Triantafyllou, K, Thosani, N, Huberty, V & Sullivan, S 2024, 'American Society for Gastrointestinal Endoscopy-European Society of Gastrointestinal Endoscopy guideline on primary endoscopic bariatric and metabolic therapies for adults with obesity', Endoscopy, vol. 56, n. 6, pagg. 437-456. https://doi.org/10.1055/a-2292-2494

TY - JOUR

T1 - American Society for Gastrointestinal Endoscopy-European Society of Gastrointestinal Endoscopy guideline on primary endoscopic bariatric and metabolic therapies for adults with obesity

AU - Jirapinyo, Pichamol

AU - Hadefi, Alia

AU - Thompson, Christopher C

AU - Patai, Árpád V

AU - Pannala, Rahul

AU - Goelder, Stefan K

AU - Kushnir, Vladimir

AU - Barthet, Marc

AU - Apovian, Caroline M

AU - Boskoski, Ivo

AU - Chapman, Christopher G

AU - Davidson, Paul

AU - Donatelli, Gianfranco

AU - Kumbhari, Vivek

AU - Hayee, Bu

AU - Esker, Janelle

AU - Hucl, Tomas

AU - Pryor, Aurora D

AU - Maselli, Roberta

AU - Schulman, Allison R

AU - Pattou, Francois

AU - Zelber-Sagi, Shira

AU - Bain, Paul A

AU - Durieux, Valérie

AU - Triantafyllou, Konstantinos

AU - Thosani, Nirav

AU - Huberty, Vincent

AU - Sullivan, Shelby

PY - 2024

Y1 - 2024

N2 - This joint ASGE-ESGE guideline provides an evidence-based summary and recommendations regarding the role of endoscopic bariatric and metabolic therapies (EBMTs) in the management of obesity. The document was developed using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) framework. It evaluates the efficacy and safety of EBMT devices and procedures that currently have CE mark or FDA-clearance/approval, or that had been approved within five years of document development. The guideline suggests the use of EBMTs plus lifestyle modification in patients with a BMI of ?30 kg/m 2, or with a BMI of 27.0-29.9 kg/m 2 with at least 1 obesity-related comorbidity. Furthermore, it suggests the utilization of intragastric balloons and devices for endoscopic gastric remodeling (EGR) in conjunction with lifestyle modification for this patient population.

AB - This joint ASGE-ESGE guideline provides an evidence-based summary and recommendations regarding the role of endoscopic bariatric and metabolic therapies (EBMTs) in the management of obesity. The document was developed using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) framework. It evaluates the efficacy and safety of EBMT devices and procedures that currently have CE mark or FDA-clearance/approval, or that had been approved within five years of document development. The guideline suggests the use of EBMTs plus lifestyle modification in patients with a BMI of ?30 kg/m 2, or with a BMI of 27.0-29.9 kg/m 2 with at least 1 obesity-related comorbidity. Furthermore, it suggests the utilization of intragastric balloons and devices for endoscopic gastric remodeling (EGR) in conjunction with lifestyle modification for this patient population.

KW - Endoscopy

KW - Gastrointestinal

KW - Endoscopy

KW - Gastrointestinal

UR - https://publicatt.unicatt.it/handle/10807/310320

UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85191163387&origin=inward

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85191163387&origin=inward

U2 - 10.1055/a-2292-2494

DO - 10.1055/a-2292-2494

M3 - Article

SN - 1438-8812

VL - 56

SP - 437

EP - 456

JO - Endoscopy

JF - Endoscopy

IS - 6

ER -

American Society for Gastrointestinal Endoscopy-European Society of Gastrointestinal Endoscopy guideline on primary endoscopic bariatric and metabolic therapies for adults with obesity

Abstract

All Science Journal Classification (ASJC) codes

Keywords

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo